US20150367007A1 - Reduction of infections in healthcare settings using photocatalytic compositions - Google Patents

Reduction of infections in healthcare settings using photocatalytic compositions Download PDF

Info

Publication number
US20150367007A1
US20150367007A1 US14/745,592 US201514745592A US2015367007A1 US 20150367007 A1 US20150367007 A1 US 20150367007A1 US 201514745592 A US201514745592 A US 201514745592A US 2015367007 A1 US2015367007 A1 US 2015367007A1
Authority
US
United States
Prior art keywords
infection
healthcare
infections
titanium dioxide
facility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/745,592
Other languages
English (en)
Inventor
Stewart B. Averett
Devron R. Averett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WELL Shield LLC
Original Assignee
WELL Shield LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WELL Shield LLC filed Critical WELL Shield LLC
Priority to US14/745,592 priority Critical patent/US20150367007A1/en
Publication of US20150367007A1 publication Critical patent/US20150367007A1/en
Priority to US15/263,925 priority patent/US10434203B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/08—Radiation
    • A61L2/088—Radiation using a photocatalyst or photosensitiser
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00—Disinfection, sterilisation or deodorisation of air
    • A61L9/16—Disinfection, sterilisation or deodorisation of air using physical phenomena
    • A61L9/18—Radiation
    • A61L9/20—Ultraviolet radiation
    • A61L9/205—Ultraviolet radiation using a photocatalyst or photosensitiser
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/06—Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
    • B01J21/063—Titanium; Oxides or hydroxides thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/06—Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
    • B01J21/08—Silica
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/06—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of zinc, cadmium or mercury
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J35/00—Catalysts, in general, characterised by their form or physical properties
    • B01J35/20—Catalysts, in general, characterised by their form or physical properties characterised by their non-solid state
    • B01J35/23—Catalysts, in general, characterised by their form or physical properties characterised by their non-solid state in a colloidal state
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J35/00—Catalysts, in general, characterised by their form or physical properties
    • B01J35/30—Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
    • B01J35/39—Photocatalytic properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J35/00—Catalysts, in general, characterised by their form or physical properties
    • B01J35/40—Catalysts, in general, characterised by their form or physical properties characterised by dimensions, e.g. grain size
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D1/00—Processes for applying liquids or other fluent materials
    • B05D1/02—Processes for applying liquids or other fluent materials performed by spraying
    • B05D1/04—Processes for applying liquids or other fluent materials performed by spraying involving the use of an electrostatic field
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20—Targets to be treated
    • A61L2202/25—Rooms in buildings, passenger compartments
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present disclosure relates to preventing and reducing the incidence of infectious agents found on a surface and particularly on surfaces found in healthcare settings.
  • infectious agents found in and on building structures and surfaces of objects therein can lead to various health problems.
  • Common offending infectious agents include microorganisms such as bacteria (e.g., gram negative rods such as Escherichia coli and gram-positive cocci such as Staphylococcus aureus ). These and other bacteria can cause health problems such as dermal infections, respiratory infections, intestinal infections, and kidney disease.
  • pathogenic viruses such as influenza viruses are commonly found in buildings where they spread among those occupying the structure.
  • infectious agents within healthcare settings lead to healthcare-associated infections which, in turn, result in greater than a billion dollars in excess healthcare costs annually. These infections have created a challenge for healthcare management teams due to multi-drug resistant bacteria becoming commonplace in healthcare settings such as hospices, hospitals, and assisted-living or long-term care facilities.
  • a method of reducing the incidence of healthcare-associated infections in a healthcare facility includes the step of treating at least one inanimate surface of the healthcare facility structure, or at least one object therein, or a combination thereof, with a photocatalytic composition.
  • the photocatalytic composition comprises, consists essentially of, or consists of titanium dioxide (TiO 2 ) doped with zinc and at least one other doping agent.
  • the healthcare-associated infections susceptible to treatment include bone infection, joint infection, bloodstream infection, central nervous system infection, cardiovascular system infection, pneumonia, reproductive tract infection, and surgical site infection.
  • the healthcare-associated infections susceptible to treatment include gastrointestinal infection, lower respiratory infection, upper respiratory infection, skin or soft tissue infection, bloodstream infection, eye infection, ear infection, nose infection, throat infection, mouth infection, and urinary tract infection.
  • the method is suitable for reducing the abundance in air and on surfaces of infectious agents including, but not limited to species of Acinetobacter , adenovirus, Bacillus, Burkholderia, Bordetella, Brucella , caliciviruses, herpes including zoster (chickenpox), Clostridium , corona viruses including SARS, MERS, and PEDV, Enterococcus, Escherichia , Hemophilus, hepatitis viruses A and B, influenza and parainfluenza viruses, Klebsiella, Listeria, Legionella , measles virus, mumps virus, Mycobacterium, Neisseria , norovirus, Pseudomonas , parvovirus, poliovirus, rhinovirus, respiratory syncytial virus, rotavirus, rubella, Salmonella, Streptococcus, Staphylococcus , and Vibrio .
  • infectious agents including, but not limited to species of Acinetobacter
  • infectious agents that are reduced include both those susceptible to antibiotics and, without limitation, those resistant to antibiotics such as MRSA (methicillin-resistant Staphylococcus aureus , VISA (vancomycin intermediate Staphylococcus aureus ), MRE (multiply resistant enterococci), and VRE (vancomycin-resistant enterococci).
  • MRSA methicillin-resistant Staphylococcus aureus
  • VISA vancomycin intermediate Staphylococcus aureus
  • MRE multiply resistant enterococci
  • VRE vancomycin-resistant enterococci
  • the photocatalytic composition is applied at a rate of from about 500 ft 2 per liter to about 1800 ft 2 per liter. According to one embodiment, the photocatalytic composition is applied by spraying, atomizing, coating, immersion, or dipping.
  • the incidence of healthcare-associated infections is reduced by at least 20% over a twelve month period after one treatment. According to another embodiment, the incidence of healthcare-associated infections is reduced by at least 30% over a twelve month period after one treatment.
  • the at least one inanimate surface of the healthcare facility structure includes any or all walls, fixtures, floors, and ceilings, including those parts of hallways, offices, bathrooms, elevators, stairwells, and kitchens/cafeterias, common areas, nurses' stations, and doctors' stations.
  • the at least one object of the healthcare facility includes the curtains, call buttons, computers, monitors, wall computer kiosks, blood pressure cuffs, wheelchairs, lifts, carts, and beds.
  • the photocatalytic composition utilized in the methods provided herein comprises, consists essentially of, or consists of titanium dioxide that is doped with zinc and at least one other doping agent.
  • the doping agent(s) increase the absorbance of light across the range of about 200 nm to about 500 nm.
  • the absorbance of light of wavelengths longer than about 450 nm is less than 50% the absorbance of light of wavelengths shorter than about 350.
  • the at least one other doping agent i.e., in addition to zinc
  • the titanium dioxide nanoparticles have an average particle size of from about 2 nm to about 20 nm.
  • the at least one other doping agent is silicon.
  • the at least one other doping agent is silicon dioxide.
  • the photocatalytic composition exhibits a ratio of titanium dioxide to silicon dioxide of from about 3 to about 20.
  • the photocatalytic composition exhibits a ratio of titanium dioxide to zinc from about 5 to about 150 and a ratio of titanium dioxide to silicon dioxide from about 1 to about 500.
  • the photocatalytic composition comprises, consists essentially of, or consists of (A) about 5000 to about 10000 ppm of titanium dioxide, (B) about 50 to about 150 ppm of zinc, and (C) about 300 to about 1000 ppm of silicon dioxide.
  • a method for preventing or reducing the number of infections in a human or animal population includes the step of treating inanimate surfaces of a structure occupied by the population, or at least one inanimate object present therein, or a combination thereof, with a photocatalytic composition.
  • the photocatalytic composition comprises, consists essentially of, or consists of titanium dioxide doped with zinc and at least one other doping agent.
  • the structure occupied by the population includes an agricultural facility, food-processing facility, catering facility, restaurants, hotel, motel, office, or childcare facility.
  • FIG. 1 is a graphic representation of solar energy capture of various TiO 2 compositions.
  • FIG. 2 is a graphic representation of the photocatalytic activity of various TiO 2 compositions when irradiated at 354 nm.
  • Methods of reducing the incidence of healthcare-associated infections in various healthcare settings are provided.
  • Methods for preventing or reducing the number of infections in a human or animal population are also provided.
  • the methods as provided herein reduce the abundance of various infectious agents that are commonly acquired or transmitted and are present on both animate and inanimate surfaces, including those infectious agents commonly found in healthcare settings. Further, airborne infectious agents also are reduced because such agents make contact with treated surfaces and are inactivated. By preventing and reducing the presence of such infectious agents, the incidence of various types of infection or disease is thereby reduced.
  • the phrase, “at least one” means one or more and thus includes individual components as well as mixtures/combinations.
  • doped or “doping” as used herein are understood to encompass the introduction of one or more impurities (e.g., dopant, doping agent) into a material for the purpose of modifying the properties of the material.
  • treatment and “treating” include mitigation of a pre-existing microbial disease or infestation by application or introduction of a photocatalytic composition as provided herein to an inanimate structure or object or an animate surface.
  • prevention and “prophylaxis” include reduction of the incidence or severity of disease or infestation in either individuals or populations.
  • healthcare-associated infection refers to any localized or systemic condition resulting from an adverse reaction to the presence of an infectious agent (or its toxin) that was not present and without evidence of incubation at the time of admission to a healthcare setting.
  • infectious agent includes, but is not limited to, viruses, mold, and bacteria that cause or contribute to infection or disease in the human population
  • organisms include but are not limited to species of Acinetobacter , adenovirus, Bacillus, Burkholderia, Bordetella, Brucella , caliciviruses, herpes including zoster (chickenpox), Clostridium , corona viruses including SARS, MERS, and PEDV, Enterococcus, Escherichia , Hemophilus, hepatitis viruses A and B, influenza and parainfluenza viruses, Klebsiella, Listeria, Legionella , measles virus, mumps virus, Mycobacterium, Neisseria , norovirus, Pseudomonas , parvovirus, poliovirus, rhinovirus, respiratory syncytial virus, rotavirus, rubella, Salmonella, Streptococcus, Staphylococcus , and Vibri
  • infectious agents that are reduced include both those susceptible to antibiotics and, without limitation, those resistant to antibiotics such as MRSA (methicillin-resistant Staphylococcus aureus , VISA (vancomycin intermediate Staphylococcus aureus ), MRE (multiply resistant enterococci), and VRE (vancomycin-resistant enterococci).
  • MRSA methicillin-resistant Staphylococcus aureus
  • VISA vancomycin intermediate Staphylococcus aureus
  • MRE multiply resistant enterococci
  • VRE vancomycin-resistant enterococci
  • the method includes the step of treating at least one inanimate surface of the healthcare facility structure, the objects (e.g., medical equipment) therein, or a combination thereof with a photocatalytic composition as provided herein.
  • exemplary healthcare settings that include such structures and objects include, but are not limited to, hospitals, doctors' offices, elder or specialty care homes (e.g., assisted living, long-term care) and hospices.
  • Exemplary structures of the facility subject to treatment include, but are not limited to, the walls, fixtures, floors, and ceilings, including those parts of hallways, offices, bathrooms, elevators, stairwells, and kitchens/cafeterias, common areas, nurses' stations, and doctors' stations.
  • Exemplary inanimate objects in such a setting include the various equipment or medical devices that may be present including, but not limited to, curtains, call buttons, computers, monitors, wall computer kiosks, blood pressure cuffs, wheelchairs, lifts, carts, beds, and other similar objects.
  • healthcare-associated infections that can be acquired or transmitted in a healthcare setting and susceptible to treatment with the photocatalytic compositions provided herein include, but are not limited to, bone and joint infection (e.g., osteomyelitis, disc space infection, joint or bursa infection, prosthetic joint infection), bloodstream infection, central nervous system infection (e.g., intracranial infection, meningitis, or ventriculitis), cardiovascular system infection (e.g., myocarditis, pericarditis, endocarditis, mediastinitis, arterial or venous infection), Eye/ear/nose/throat/mouth infection (e.g., conjunctivitis, ear infection, oral infection, sinusitis, upper respiratory infection, pharyngitis, laryngitis, epiglottitis), gastrointestinal system infection (e.g., gastroenteritis, gastrointestinal tract infection, hepatitis, intraabdominal infection, necrotizing enterocolitis), lower respiratory infection (e.g., bron
  • healthcare-associated infections that can be acquired or transmitted in a healthcare setting and are usceptible to treatment include gastrointestinal infection, lower respiratory infection, upper respiratory infection, skin or soft tissue infection, bloodstream infection, eye infection, ear infection, nose infection, throat infection, mouth infection, and urinary tract infection.
  • the incidence of healthcare-associated infections is reduced by at least 20% over a twelve month period after one treatment as provided herein. According to a preferred embodiment, the incidence of healthcare-associated infections is reduced by at least 30% over a twelve month period after one treatment as provided herein.
  • compositions as provided herein may be applied in any known or suitable manner, including using application techniques such as spraying (e.g., electrostatic), atomizing, coating, immersion, or dipping.
  • application techniques such as spraying (e.g., electrostatic), atomizing, coating, immersion, or dipping.
  • the best method of application may vary according to the nature of the surface to be coated. For many settings a preferred method is to use electrostatic spray, wherein droplets of the aqueous composition ranging in size from 5 micrometers to 100 micrometers are afforded a small electrical charge so that the droplets are attracted to the surface to be coated.
  • the coating is applied as a series of two to five spraying steps with drying allowed between each step.
  • the photocatalytic coating can be applied at a rate of from about 500 ft 2 per liter to about 1500 ft 2 per liter.
  • a method for preventing or reducing the number of infections in a human or animal population includes treating inanimate structures used by the human or animal population, the inanimate objects that may be found within such structures, or a combination thereof, with a photocatalytic composition as provided herein.
  • the step of treating the inanimate structures may include treating either a finished structure or a structure under construction.
  • Exemplary settings that include such structures and objects include, but are not limited to, agricultural facilities, food-processing facilities, catering facilities, restaurants, hotels, motels, and childcare facilities.
  • Exemplary parts of the structures that can be treated include, but are not limited to, walls, fixtures, floors, and ceilings, including those parts of hallways, offices, bathrooms, elevators, stairwells, and kitchens.
  • the methods as provided herein utilize photocatalytic compositions that include titanium dioxide (TiO 2 ) nanoparticles, which are useful in the prevention and reduction of infectious agents found on a surface and particularly useful in the reduction of healthcare-associated infections.
  • the photocatalytic compositions as provided herein, including any nanoparticles therein, are free of any polymer or polymer composition (e.g., polymer-stabilized inorganic composition).
  • the photocatalytic compositions as provided herein can be used to treat both animate and inanimate surfaces in a variety of environments where an infectious agent is located.
  • the photocatalytic compositions provided herein contain only well characterized and safe materials, can be easily applied to surfaces using ordinary spray equipment, exhibit photocatalytic activity, and are effective in settings of low UV irradiance, including interior artificial lighting.
  • the methods as provided herein utilize photocatalytic compositions that comprise, consist essentially of, or consist of titanium dioxide (TiO 2 ) doped with zinc and at least one other doping agent.
  • Doping agents suitable in the photocatalytic compositions provided herein, in addition to zinc include Ag, Si, C, S, Fe, Mo, Ru, Cu, Os, Re, Rh, Sn, Pt, Li, Na, and K, and combinations thereof.
  • Particularly preferred doping agents include zinc and silicon.
  • the composition comprises, consists essentially of, or consists of titanium dioxide doped with zinc and the ratio of titanium dioxide to zinc is from about 5 to about 150. According to a preferred embodiment, the ratio of titanium dioxide to zinc is from about 40 to about 100.
  • the photocatalytic composition can further comprise, consist essentially of, or consist of silicon dioxide (SiO 2 ). According to such an embodiment, the ratio of titanium dioxide to silicon dioxide can range from about 1 to about 500. According to a preferred embodiment, the ratio of titanium dioxide to silicon dioxide is from about 3 to about 20. According to one embodiment, the titanium dioxide nanoparticles as provided herein have an average particle size of from about 2 nm to about 20 nm.
  • the photocatalytic composition as provided herein comprises, consists essentially of, or consists of from about 5000 to about 10000 ppm of titanium dioxide, from about 50 to about 150 ppm of zinc, and from about 300 to about 1000 ppm of silicon dioxide.
  • the photocatalytic composition as provided herein absorbs electromagnetic radiation in a wavelength range of from about 200 nm to about 500 nm.
  • the absorbance of light of wavelengths longer than about 450 nm is less than 50% the absorbance of light of wavelengths shorter than about 350 nm.
  • nanoscale TiO 2 Absorption characteristics of nanoscale TiO 2 were compared to nanoscale TiO 2 doped with two differing zinc levels and SiO 2 , over the wavelength range of 350 nm to 500 nm.
  • the nanoparticle compositions were manufactured by a modified sol-gel process, to produce formulations containing nanoparticles of anatase TiO 2 whose average size was 6 to 7 nm.
  • Zinc was incorporated as a doping agent to provide either low zinc content (0.125% relative to TiO 2 ) or high zinc content (1.25% relative to TiO 2 ).
  • SiO 2 was an additional dopant, it was present at 10% relative to TiO 2 .
  • the preparations were dried and absorbance was measured using standard methods for obtaining diffuse reflectance spectra (DRS) of powders. The solar irradiance (hemispherical, 37 degree tilt) from ASTM G173-03 across this spectral range is shown for reference, (See FIG. 1 ).
  • the TiO 2 preparations doped with hetero-atoms absorb more strongly than otherwise similar undoped TiO 2 in the near-UV and violet region of the spectrum.
  • the doped preparations absorb 25 to 35 percent more of the energy available from 400 to 450 nm, a region of the spectrum that is present in typical interior light as well as sunlight.
  • Example 1 The four formulations described in Example 1 were tested for their photocatalytic activity in a standardized system. Each preparation was suspended in water at approximately 8000 ppm and applied to a glass panel using a robotic high volume low pressure sprayer, and allowed to dry for 24 hours. These panels were each attached to a glass tube to form a container, into which was placed 30 ml of an aqueous solution of methylene blue at a concentration providing an optical density of 2.3 at 664 nm. The tubes were covered with a glass panel and subjected to illumination at an energy density of approximately 0.5 mW/cm 2 from a lamp (GE item F18T8/BLB) affording ultraviolet illumination at 354 nm. This lamp provides no light at wavelengths below 300 nm or above 400 nm. The optical density of the methylene blue solution in each sample was monitored over a period of 48 hours and is shown in FIG. 2 .
  • a lamp GE item F18T8/BLB
  • FIG. 2 shows that the nanocoatings caused a decline in optical density, which results from photocatalytic degradation of the organic dye methylene blue.
  • Example 1 The four formulations described in Example 1 were tested for their photocatalytic activity in a second system, in which the experimental illumination was changed to more closely mimic relevant illumination such as daylight or interior light, which are deficient in the ultraviolet energy used in Example 2.
  • the nanoparticle formulations were evaluated as colloidal suspensions in 20 mM phosphate buffer, pH 7.2, rather than on a static surface.
  • the experiment was performed in a 96-well plate format, in which each well contained methylene blue (observed OD 655 ranging from 0.05 to 0.5) and a nanoparticle formulation or appropriate controls in a final volume of 200 microliters.
  • the plate was illuminated from a distance of 20 cm with light from two Sylvania Gro-Lux lamps (F20 T12 GRO/AQ).
  • compositions of the four preparations tested in this experiment were independently verified by the analytical technique known as ICP-AES (inductively coupled plasma atomic emission spectrometry), which demonstrated their equivalent TiO 2 content and variations in Si and Zn composition as described in Example 1.
  • the nanoparticle preparations were diluted in buffer to provide final concentrations of 75 ppm of titanium dioxide of each formulation, with twenty replicate wells of each formulation. After a short period of equilibration in the dark, each plate was exposed to illumination with shaking, and optical density at 655 nm was measured at multiple times over using a Molecular Devices SpectraMax Plus spectrophotometer. The observed linear declines in optical density due to each formulation were measured to give the rates summarized in Table 1.
  • Trial 1 TiO 2 , low Zn 0.0017* 0.0016 TiO 2 , low Zn, high Si 0.0020 Not tested TiO 2 , high Zn, high Si 0.0019 Not tested TiO 2 only Not tested 0.0013 *All values reported are the decline in optical density at 655 nm, per minute
  • a photocatalytic composition including titanium dioxide nanoparticles doped with zinc and silicon dioxide was prepared.
  • the individual nanoparticles were approximately six to ten nanometers in dimension, and were dispersed in water to provide about 8000 ppm TiO 2 , about 100 ppm Zn, and about 500 ppm SiO 2 .
  • This dispersed colloidal suspension of doped nanoparticles was used to coat essentially all accessible surfaces in a 42 bed health care facility that provides long term acute care services to patients after surgery and other medical procedures.
  • the coating was applied using the following procedure. Vacant rooms and bathrooms were thoroughly cleaned by housekeeping staff, including removal of all linens and surface disinfection according to institutional procedures. The photocatalytic coating was then applied using electrostatic spray at a rate of about 1200 ft 2 per liter. All objects in the room were coated, including both hard and soft surface furniture and nearby walls, window and privacy curtains, and equipment such as call buttons and remote controls. Bathroom walls, fixtures, and floors were specifically coated. A minimum of 15 minutes was allowed for drying of coated surfaces, after which the room was ready for occupancy. In addition to patient rooms, all common areas, including hallways, offices, visitor restrooms, elevators, stairwells, kitchen, and nurse's stations (including computers) were coated. Equipment was also coated, including wall computer kiosks, blood pressure cuffs, wheelchairs, lifts, carts, and other similar surfaces.
  • the healthcare facility made no changes to institutional infection control processes or procedures.
  • the number of infections were recorded in compliance with existing institutional protocols.
  • Table 2 reports the number of infections occurring in each quarter of the year following treatment, compared with the number of infections at the same institution during the same quarter of the year prior to treatment. Infections were fewer in every quarter after treatment than in any quarter prior to treatment. When summed over the entire assessment period, infections declined 40% in the year following surface coating with the photocatalytic composition.
  • Example 4 The composition described in Example 4 was applied using the procedure described in Example 4 to a 250 bed health care facility that provides sub-acute long term residential care. Similar to Example 4, no change was made to institutional processes or procedures, and infections occurring in the facility were enumerated in accord with standard protocols. Table 3 reports the number of infections occurring in each quarter of the year following treatment, compared with the number of infections at the same institution during the same quarter of the year prior to treatment. Infections were fewer in every quarter after treatment compared to any quarter prior to treatment. When summed over the entire assessment period, infections declined 32% in the year following surface coating with the photocatalytic composition.
  • the larger size of this facility allowed an examination of selected categories of infections, as defined by the USA Centers for Disease Control (CDC), because of the larger total number of events.
  • CDC USA Centers for Disease Control
  • the absolute numbers of infections and the actual patient population were used to calculate the rate of each infection for each month of the evaluation interval.
  • the rates were reported in the unit of events per 1000 patient days. These monthly rates were averaged for the year before application of the coating and the year after application, and compared.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Catalysts (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
US14/745,592 2014-06-23 2015-06-22 Reduction of infections in healthcare settings using photocatalytic compositions Abandoned US20150367007A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/745,592 US20150367007A1 (en) 2014-06-23 2015-06-22 Reduction of infections in healthcare settings using photocatalytic compositions
US15/263,925 US10434203B2 (en) 2014-06-23 2016-09-13 Reduction of infections in healthcare settings using photocatalytic compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462015596P 2014-06-23 2014-06-23
US14/745,592 US20150367007A1 (en) 2014-06-23 2015-06-22 Reduction of infections in healthcare settings using photocatalytic compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/263,925 Continuation US10434203B2 (en) 2014-06-23 2016-09-13 Reduction of infections in healthcare settings using photocatalytic compositions

Publications (1)

Publication Number Publication Date
US20150367007A1 true US20150367007A1 (en) 2015-12-24

Family

ID=54868693

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/745,592 Abandoned US20150367007A1 (en) 2014-06-23 2015-06-22 Reduction of infections in healthcare settings using photocatalytic compositions
US15/263,925 Active 2036-03-11 US10434203B2 (en) 2014-06-23 2016-09-13 Reduction of infections in healthcare settings using photocatalytic compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/263,925 Active 2036-03-11 US10434203B2 (en) 2014-06-23 2016-09-13 Reduction of infections in healthcare settings using photocatalytic compositions

Country Status (11)

Country Link
US (2) US20150367007A1 (ko)
EP (1) EP3160233A4 (ko)
JP (1) JP6749320B2 (ko)
KR (1) KR102493213B1 (ko)
CN (1) CN106535639A (ko)
AU (1) AU2015280348B2 (ko)
CA (1) CA2953515C (ko)
IL (1) IL249488B (ko)
MX (1) MX2016016865A (ko)
WO (1) WO2015200161A1 (ko)
ZA (1) ZA201700244B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11819580B2 (en) 2016-10-18 2023-11-21 PurWorld Technologies LLC Method of chemically disinfecting a vehicle
CN111107747A (zh) * 2018-08-29 2020-05-05 株式会社日吉 对于军团菌属菌的消毒剂、水处理方法、浴槽水用添加剂和空调冷却塔水用添加剂
US20210353806A1 (en) * 2020-05-14 2021-11-18 Healthe, Inc. Elevator sterilization system and associated methods
WO2022040379A1 (en) * 2020-08-20 2022-02-24 Current Lighting Solutions, Llc System and method to disinfect a room using ultraviolet light and a photocatalyst
KR102208783B1 (ko) * 2020-10-08 2021-01-28 애드문코퍼레이션 주식회사 분무 조성물 및 이의 제조방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050177957A1 (en) * 2002-01-07 2005-08-18 Long Jack W. Topical treatment for carpet and textiles and topically treated carpet and textile products
CN1899687A (zh) * 2006-07-21 2007-01-24 浙江大学 锌、硅共掺杂纳米二氧化钛光催化剂及其制备方法和应用
US20080187457A1 (en) * 2007-02-05 2008-08-07 Mangiardi John R Antibacterial Titanium Dioxide Compositions
US20120308630A1 (en) * 2011-05-04 2012-12-06 Averett Steward B Titanium dioxide photocatalytic compositions and uses thereof
US20130180932A1 (en) * 2012-01-12 2013-07-18 Nitto Denko Corporation Transparent Photocatalyst Coating

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3279999D1 (en) 1981-09-30 1989-11-30 Nat Res Dev Compositions comprising encapsulated particles
US6387844B1 (en) 1994-10-31 2002-05-14 Akira Fujishima Titanium dioxide photocatalyst
FR2776944B1 (fr) 1998-04-03 2000-05-12 Ahlstrom Paper Group Research Composition photocatalytique
KR20000009824A (ko) 1998-07-29 2000-02-15 여광웅 동식물성 유기폐기물의 멸균장치
JP3458948B2 (ja) 1999-07-01 2003-10-20 博 河合 植物茎葉散布用組成物およびその使用方法
KR100357765B1 (ko) 1999-11-25 2002-10-25 (주)바이오세라 광반도성 탈취/항균 필터의 제조 방법 및 이에 의해 제조된 광반도성 탈취/항균필터
IL133364A0 (en) 1999-12-07 2001-04-30 Progeny Biolog Systems A method and system for treatment of animal waste
JP2001286226A (ja) 2000-04-06 2001-10-16 Tsunetaka Yokoyama 農業用ビニールハウスの天井等に酸化チタン及びセラミックス粉末を接着させる方法
JP2001314882A (ja) 2000-05-09 2001-11-13 Dreams:Kk バイオ浄化資材およびその製造方法
US20020187082A1 (en) 2001-06-06 2002-12-12 Chang-Yu Wu Photocatalyst coated magnetic composite particle
EP1468737A4 (en) 2002-01-21 2005-09-21 Sumitomo Titanium Corp PHOTOCATALYTIC COMPOSITE MATERIAL AND PROCESS FOR PREPARING THE SAME
KR100845963B1 (ko) 2002-04-16 2008-07-11 가부시끼가이샤 르네사스 테크놀로지 반도체장치 및 그 제조 방법
HK1050811A2 (en) 2002-05-09 2003-06-13 Environmentalcare Ltd A fluid purification and disinfection device
US7449245B2 (en) 2002-07-09 2008-11-11 Leibniz-Institut Fuer Neue Materialien Gemeinnuetzige Gmbh Substrates comprising a photocatalytic TiO2 layer
US20040060677A1 (en) 2002-09-27 2004-04-01 Ching-Chung Huang Multi-functional paper and a method making the same
US7001571B2 (en) 2002-10-24 2006-02-21 Georgia Tech Research Corporation Systems and methods for disinfection
CN1777653A (zh) 2003-04-18 2006-05-24 默克专利股份有限公司 抗微生物颜料
JP2005040769A (ja) 2003-07-25 2005-02-17 Yukio Hirose 水質改善構造体およびこれを用いた水質改善方法
WO2005072680A2 (en) 2004-01-28 2005-08-11 Oxonica, Ltd Surface-doped particles of ti02 or zno and their use
JP4587302B2 (ja) * 2005-02-28 2010-11-24 財団法人電力中央研究所 医家向け抗菌製品
FR2884147B3 (fr) * 2005-04-11 2008-06-13 Saint Gobain Substrat microbicide
JP2006321721A (ja) 2005-05-17 2006-11-30 Shinto Paint Co Ltd 開花、結実促進剤
DE102005035311A1 (de) * 2005-07-28 2007-02-01 Degussa Ag Zubereitung, enthaltend ein photokatalytisch aktives Metalloxidpulver und ein Netzmittel
ITMI20051558A1 (it) 2005-08-09 2007-02-10 Isagro Spa Miscele e-o composizioni sinergiche cin elevata attivita'fungicida
ITIS20050002A1 (it) 2005-09-01 2007-03-02 Jokero Inv Srl Filtri fotocatalitici ricoperti con sospensioni di biossido di titanio ed altri composti e metodi per otteneri detti filtri.
FR2900351B1 (fr) 2006-04-26 2008-06-13 Commissariat Energie Atomique Procede de preparation d'une couche nanoporeuse de nanoparticules et couche ainsi obtenue
PL2079302T3 (pl) 2006-10-12 2014-08-29 Nm Tech Nanomaterials Microdevice Tech Ltd Zastosowanie kompozycji o właściwościach przeciwdrobnoustrojowych
JP2010516719A (ja) 2007-01-23 2010-05-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗菌性組成物
WO2008093398A1 (ja) 2007-01-30 2008-08-07 Asics Corporation シューズの製造方法、及びシューズ
WO2008135093A1 (en) 2007-05-08 2008-11-13 Nm Tech Nanomaterials Microdevice Technology Ltd. Products comprising an anti-microbial composition based on titanium dioxide nanoparticles
WO2009030641A1 (en) 2007-09-06 2009-03-12 Vitec Speciality Chemicals Limited Water-stabilized antimicrobial organosilane compositions, and methods for using the same
US20090068089A1 (en) 2007-09-08 2009-03-12 Quaid-E-Azam University Novel method of manufacture of silver oxide nano particles
JP2009084542A (ja) 2007-10-02 2009-04-23 Sun Medic Corp 抗菌性水性組成物
US20090104086A1 (en) 2007-10-19 2009-04-23 Adam Zax Photocatalytic titanium dioxide nanocrystals
US20090169425A1 (en) 2007-12-27 2009-07-02 Industry-Academic Cooperation Foundation, Yonsei University Apparatus and method for disinfecting food using photo-catalytic reaction of titanium dioxide and ultraviolet rays
US20100021710A1 (en) 2008-07-08 2010-01-28 Ngimat Co. Antimicrobial coatings
MX2011010249A (es) 2009-04-02 2011-11-04 Basf Se Metodo para combatir hongos dañinos.
WO2011033377A2 (en) 2009-09-17 2011-03-24 Vive Nano, Inc. Multifunctional nanocomposites
CN101905166B (zh) 2010-07-27 2012-07-25 中国地质大学（武汉） 一种可磁分离的氮掺杂TiO2光催化剂及其制备方法
JP5812488B2 (ja) * 2011-10-12 2015-11-11 昭和電工株式会社 抗菌抗ウイルス性組成物及びその製造方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050177957A1 (en) * 2002-01-07 2005-08-18 Long Jack W. Topical treatment for carpet and textiles and topically treated carpet and textile products
CN1899687A (zh) * 2006-07-21 2007-01-24 浙江大学 锌、硅共掺杂纳米二氧化钛光催化剂及其制备方法和应用
US20080187457A1 (en) * 2007-02-05 2008-08-07 Mangiardi John R Antibacterial Titanium Dioxide Compositions
US20120308630A1 (en) * 2011-05-04 2012-12-06 Averett Steward B Titanium dioxide photocatalytic compositions and uses thereof
US20130180932A1 (en) * 2012-01-12 2013-07-18 Nitto Denko Corporation Transparent Photocatalyst Coating

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
English translation of Document No. CN 1899687 A provided by espacenet.com: Description CN1899687. *
Envirocare Webpage. http://www.altimategogreen.com. Accessed 6/3/2016. *
Leng et al., Efficacy of titanium dioxide compounds in preventing environmental contamination by meticillin resistant Staphylococcus aureus (MRSA), 2013, International Journal of Infection Control, p. 1-8 *

Also Published As

Publication number Publication date
KR20170048318A (ko) 2017-05-08
CA2953515A1 (en) 2015-12-30
JP2017523892A (ja) 2017-08-24
WO2015200161A1 (en) 2015-12-30
IL249488B (en) 2020-07-30
CA2953515C (en) 2023-04-25
EP3160233A4 (en) 2018-03-07
US10434203B2 (en) 2019-10-08
AU2015280348A1 (en) 2017-02-02
US20160375164A1 (en) 2016-12-29
JP6749320B2 (ja) 2020-09-02
NZ728027A (en) 2023-12-22
CN106535639A (zh) 2017-03-22
KR102493213B1 (ko) 2023-01-27
EP3160233A1 (en) 2017-05-03
MX2016016865A (es) 2017-07-27
ZA201700244B (en) 2022-05-25
AU2015280348B2 (en) 2019-05-16
IL249488A0 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
US10434203B2 (en) Reduction of infections in healthcare settings using photocatalytic compositions
García de Abajo et al. Back to normal: an old physics route to reduce SARS-CoV-2 transmission in indoor spaces
Nardell Air disinfection for airborne infection control with a focus on COVID‐19: why germicidal UV is essential
Hobday et al. Roles of sunlight and natural ventilation for controlling infection: historical and current perspectives
US20090104086A1 (en) Photocatalytic titanium dioxide nanocrystals
Weber et al. Continuous room decontamination technologies
US9724440B2 (en) Environmental cleaning and antimicrobial lighting component and fixture
Taneja et al. Hydrogen peroxide vapour for decontaminating air-conditioning ducts and rooms of an emergency complex in northern India: time to move on
De Jong et al. Pre–post evaluation of effects of a titanium dioxide coating on environmental contamination of an intensive care unit: the TITANIC study
JP2017523892A5 (ko)
Salonen et al. Methods for infection prevention in the built environment—a mini-review
Chow et al. Efficacy of titanium dioxide compounds in preventing environmental contamination by meticillin resistant Staphylococcus aureus (MRSA)
US11013822B1 (en) Smallest particulate absorber
EP4185340A1 (en) Nanoparticles, nanofunctionalised substrate and device with antiviral and/or antibacterial and/or antifungal photocatalytic activity
Emmanuel et al. Environmental sustainability for infection prevention and control (ipc) in healthcare facilities
Damiano et al. The susceptibility of multidrug resistant and biofilm forming Klebsiella pneumoniae and Escherichia coli to antiseptic agents used for preoperative skin preparations at zonal referral hospital in Mwanza, Tanzania
Dunnill et al. Antimicrobial coatings for ‘self-sterilisation’
Elfakhri Antibacterial activity of novel self-disinfecting surface coatings
Emmanuel et al. Infection Control Through Environmental Design
Luksamijarulkul et al. Indoor air microbial counts in dormitory of nursing students, Bangkok
US20050013882A1 (en) Phyto fluid
Decraene et al. Enhancement by nanogold of the efficacy of a light-activated antimicrobial coating
Mudd Air-Borne Infection. The Rationale and Means of Disinfection of Air
Narouei et al. Effects of Germicidal Far-UVC on Indoor Air Quality in an Office Setting
Lager et al. RESEARCH OF THE BERGER LAMP EFFECTIVITY AGAINST THE MICROBIAL AIR CONTAMINATION

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION